CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
Lusi ZhangSarah Jane BrownYuting ShanAdam M LeeJosiah D AllenSeenae EumJose De LeonJeffrey R BishopPublished in: Pharmacotherapy (2020)
Genetically defined impaired CYP2D6 activity is associated with increased exposure of both risperidone and risperidone + 9-hydroxyrisperidone in adults receiving oral formulations. Additional studies are needed to quantify the clinical impact of these relationships.
Keyphrases